Logiscreen

Trillium Therapeutics Inc

$19.86
Market Cap 2.08B
ROE -7.9%
Gross Margin 0.0%
Debt/Equity 0.0
Current Ratio 12.0
Revenue QoQ 0.0%
EPS QoQ 0.3%
F-Score 2

About

Trillium is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Our two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Fair Value

Trading at a discount to sector peers

P/E
31.99
vs median 31.50
P/B
8.56
vs median 2.17
ROE
-0.08
vs median 0.09

Lower quality - review fundamentals carefully

Mid-cap company with growth potential

Similar companies

MLYSPHVSKODELVNBCRXRXRX
Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics